Karuna intends to execute on its broader ambitions for lead program KarXT xanomeline/trospium chloride beyond schizophrenia, including development in at least two new indications, after raising $68 million in series B funding.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,